The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

An AI researcher and former teacher shares insights on how new technologies will affect math instruction and learning.

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

We recently published a list of Jim Cramer Looked At These 23 Stocks Recently. In this article, we are going to take a look ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Professors from NYU and the University of British Columbia have resolved the Kakeya set conjecture in three dimensions.

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $492.69, indicating a -1.96% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Gemini 2.5 Pro is a multimodal, reasoning model that outperforms competitors from OpenAI, Anthropic, and DeepSeek on key ...